Advanced Bifurcation Systems Inc. Receives FDA Breakthrough Device Designation

2023-10-23
LIVERMORE, Calif., Oct. 23, 2023 /PRNewswire/ -- Advanced Bifurcation Systems Inc. (ABS), a pioneer in comprehensive solutions for bifurcation lesions in coronary angioplasty, today announced that it has received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its novel coronary artery bifurcation stenting technology.
Continue Reading
This prestigious designation is granted to devices that have the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases. The ABS platform stands out for its innovative approach to treating coronary artery bifurcations, reducing the need for open-heart surgery, hospitalizations, and repeat procedures, thereby significantly improving patient care outcomes and reducing healthcare costs.
"Advanced Bifurcation Systems receives FDA Breakthrough Device Designation"
Post this
"The FDA's Breakthrough Device Designation is a testament to the potential of our technology to address a critical unmet need in interventional cardiology," said Dr. Mehran Khorsandi, CEO of Advanced Bifurcation Systems. "Our unique stenting technology is designed to simplify procedures, improve patient outcomes, and reduce angioplasty times, marking a significant advancement in coronary treatments."
The Breakthrough Devices Program will offer ABS the opportunity for more interactive and efficient communication with the FDA during the premarket review phase. This designation also allows for a prioritized review of the technology, highlighting its significance and potential for positive patient impact.
For more information about Advanced Bifurcation Systems and its revolutionary approach to coronary artery bifurcation stenting, visit www.advancedbifurcation.com
Contacts:
Advanced Bifurcation Systems, Inc.
Dr. Mehran Khorsandi
Chairman & CEO
[email protected]
Henry Bourang
President & COO
[email protected]
Ken Richards
CAO/CFO
[email protected]
SOURCE Advanced Bifurcation Systems
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。